I cannot concur with your characterization of the ICGN buyout as pathetic insofar as the buyout price of $6 is a 150% premium to ICGN’s unaffected share price. This is one of the highest premiums in any recent biotech acquisition (#msg-65401590).
Assuming the share price must go up when a company in play gets acquired is just as silly as assuming the share price must go up when a company gets FDA approval. People on this board are too smart for that, IMO.
Market Data 
Markets 
AI
